Dine JL et al.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.Breast Cancer Res Treat 155:235-51 (2016).
Hsieh MS et al.The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.Oncotarget 7:36956-36970 (2016).
Qu XH et al.Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer.Oncol Lett 10:1677-1685 (2015).
Leconet W et al.Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.Oncogene N/A:N/A (2013).
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"